JP2024504260A5 - - Google Patents
Info
- Publication number
- JP2024504260A5 JP2024504260A5 JP2023537587A JP2023537587A JP2024504260A5 JP 2024504260 A5 JP2024504260 A5 JP 2024504260A5 JP 2023537587 A JP2023537587 A JP 2023537587A JP 2023537587 A JP2023537587 A JP 2023537587A JP 2024504260 A5 JP2024504260 A5 JP 2024504260A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- approximately
- subject
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126294P | 2020-12-16 | 2020-12-16 | |
| US63/126,294 | 2020-12-16 | ||
| US202163168414P | 2021-03-31 | 2021-03-31 | |
| US63/168,414 | 2021-03-31 | ||
| US202163170805P | 2021-04-05 | 2021-04-05 | |
| US63/170,805 | 2021-04-05 | ||
| PCT/US2021/063639 WO2022132981A1 (en) | 2020-12-16 | 2021-12-15 | Methods for modulation of and sensitization to serine and glycine limitation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504260A JP2024504260A (ja) | 2024-01-31 |
| JP2024504260A5 true JP2024504260A5 (https=) | 2024-12-20 |
Family
ID=82023934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537587A Pending JP2024504260A (ja) | 2020-12-16 | 2021-12-15 | セリンおよびグリシンの制限の調節およびそれらの制限に対する感受性化のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220193447A1 (https=) |
| EP (1) | EP4262787A4 (https=) |
| JP (1) | JP2024504260A (https=) |
| AU (1) | AU2021403024A1 (https=) |
| CA (1) | CA3205385A1 (https=) |
| WO (1) | WO2022132981A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109069462A (zh) | 2016-02-23 | 2018-12-21 | 癌症研究科技有限公司 | 缺乏至少两种非必需氨基酸的膳食产品 |
| JP2023530235A (ja) | 2020-06-03 | 2023-07-14 | フェス・セラピューティクス，インコーポレーテッド | 個別化された処置方法のための製剤 |
| WO2021247923A1 (en) | 2020-06-04 | 2021-12-09 | Faeth Therapeutics, Inc. | Personalized methods of treating cancer |
| WO2025029650A1 (en) | 2023-07-28 | 2025-02-06 | Li Xiyan | Nutritionally modified diets comprising aminoacids for use in treating a disease |
| WO2025208086A1 (en) * | 2024-03-29 | 2025-10-02 | Faeth Therapeutics, Inc. | Dietary regimens and methods for treatment of colorectal cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107921133A (zh) * | 2015-09-04 | 2018-04-17 | 国立大学法人大阪大学 | 癌症的饮食疗法开发 |
| CN109069462A (zh) * | 2016-02-23 | 2018-12-21 | 癌症研究科技有限公司 | 缺乏至少两种非必需氨基酸的膳食产品 |
| JP7623784B2 (ja) * | 2016-10-13 | 2025-01-29 | ジュノー セラピューティクス インコーポレイテッド | トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物 |
| CA3119300A1 (en) * | 2017-11-13 | 2019-05-16 | Cancer Research Technology Ltd. | Dietary product |
| WO2021247923A1 (en) * | 2020-06-04 | 2021-12-09 | Faeth Therapeutics, Inc. | Personalized methods of treating cancer |
-
2021
- 2021-12-15 JP JP2023537587A patent/JP2024504260A/ja active Pending
- 2021-12-15 CA CA3205385A patent/CA3205385A1/en active Pending
- 2021-12-15 EP EP21907754.2A patent/EP4262787A4/en active Pending
- 2021-12-15 WO PCT/US2021/063639 patent/WO2022132981A1/en not_active Ceased
- 2021-12-15 US US17/551,725 patent/US20220193447A1/en active Pending
- 2021-12-15 AU AU2021403024A patent/AU2021403024A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024504260A5 (https=) | ||
| AU2011287292B2 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| JP2021523122A5 (https=) | ||
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JP2021513540A5 (https=) | ||
| JP2021513541A5 (https=) | ||
| JP2021510697A5 (https=) | ||
| JP2023507190A5 (https=) | ||
| CN101547705A (zh) | 用于治疗新生物的组合物和方法 | |
| RU2007135167A (ru) | Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| JP2021523233A5 (https=) | ||
| JP2022541591A5 (https=) | ||
| US20200399377A1 (en) | Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen | |
| JP2019516767A (ja) | 癌の治療のためのペンブロリズマブとアベマシクリブとの組合せ | |
| JP2024534602A5 (https=) | ||
| JP2021520368A5 (https=) | ||
| JP2023519807A5 (https=) | ||
| US20230398229A1 (en) | Antibody drug conjugates comprising sting agonists, combinations and methods of use | |
| JP2023502876A5 (https=) | ||
| JP2025515092A5 (https=) | ||
| JP2023520771A5 (https=) | ||
| JP2023505222A5 (https=) | ||
| JP2022517415A5 (https=) | ||
| JP2025509567A5 (https=) |